For the almost 500 decades, naturally occurring plant products always showed a narrative role to society for their effectiveness against several diseases. Carvone is a mono-terpenoid which is obtained as an essential oil obtained from Anethum graveolens (dill) and Carum carvi (caraway) oils, S(+) enantiomer and the (-R) enantiomer of carvone as a primary constituent of Mentha spicata (spearmint) oil also found in Calamintha officinalis (calamint) oil. As Carvone has shown a very less toxic effect. S(+) Carvone also acts as an anti-epileptic agent, (S &R) Carvone has shown much more potent activity when compared to (R) species of carvone. By performing In-silico docking studies of S(+) Carvone it has been observed that it is quite safe and potentially effective as an anticonvulsant agent, antispasmodic agent, antifungal agent, also as a cardiovascular agent etc. Carvone has a high permeability to GI absorption and also it follows the Lipinski rule (0 violations). Although, Carvone has less toxicity while crossing the blood-brain barrier. Docking studies of carvone is suggesting that it can be used for many advancements of the drug to achieve potent results in different pharmacological aspects.
The main inhibitory neurotransmitter in the mammalian brain is 4-aminobutyric acid (GABA). Phthalimide acts as a sodium channel antagonist, one of the finest targets for treating epilepsy is the sodium channel and JNK kinase activity is inhibited to treat epilepsy. a novel compound with multiple targets of action for the treatment of epilepsy also anti-oxidant activity has been designed. The compounds are designed in two series aldehydes and aniline. Docking of all the designed compounds has been done with the suitable protein GABA-AT, sodium channel, JNK protein, and anti-oxidant from protein bank. QSAR was done for constructing many linear regression models. In combination with the developed Docking and QSAR outcomes, ADMET has been performed for the active compounds. The result shows that 11 of the compounds have excellent binding energy in docking with all the receptors and also have good QSAR results and follow the ADMET. The structural understanding of human GABA-AT inhibition was obtained from molecular dynamics simulation studies for compound no. 11 at 5 nanoseconds. Synthesis and pharmacological activity also suggest that the designed compound no.11 be considered the best Novel Compound.
22 January 2026 in Bulletin of the National Research Centre
Single-atom catalysts (SACs) have emerged as a powerful class of nano-catalysts for tumor therapy due to their well-defined active sites and exceptional ca
Chronic kidney disease (CKD) is a prevalent and complex disorder in the current clinical landscape. Adequate intake of essential micronutrients is required